Amylyx Pharmaceuticals is a clinical-stage company dedicated to developing innovative treatments for diseases with high unmet needs, such as post-bariatric hypoglycemia, Wolfram syndrome, and amyotrophic lateral sclerosis (ALS). With a focus on addressing these challenging conditions, Amylyx aims to significantly improve patient outcomes and reshape the approach to healthcare in these areas.
